Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Bulgaria

Outlook For Drugmakers In CEE Stable For Q112

October 2011 | Industry Trend Analysis

BMI View: Central and Eastern Europe (CEE)'s attractiveness to drugmakers has improved. BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets according to their risk/reward profile, show that the region's score increased from 52.9 out of 100 in Q411 to 53.3 in Q112, up by of 0.7%. However, the main factor contributing to this quarter's improvement has been new population projections, providing small improvement to our country rewards indicator. Global macroeconomic headwinds continue to lead to downward revisions to BMI's economic growth outlook for the region. While our drug expenditure projections remain broadly stable, the potential for long-term downward revisions is high

To read the full article, please choose one of the following options:

Subcribers please log in

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries